Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CASTLE BIOSCIENCES INC (CSTL)

Castle Biosciences Q3 revenue up 24% to $102.9M; 2026 guidance raised, net loss widens

Mixed Impact 4 of 5 earnings Written later

Castle Biosciences reported third-quarter 2026 revenue of $102.9 million, up from $83.0 million a year earlier, and raised its full-year 2026 revenue guidance to $385-395 million from $365-375 million. The company's net loss widened to $4.1 million, or $0.13 per share, from $0.5 million, or $0.02 per share, in the same period of 2025.

Key points

  • Q3 2026 revenue was $102.9 million, compared with $83.0 million in Q3 2025.
  • Q3 2026 net loss was $4.1 million, or $0.13 per share, versus $0.5 million, or $0.02 per share, a year earlier.
  • 2026 total revenue guidance raised to $385-395 million from $365-375 million; positive Adjusted EBITDA expected for Q4 2026, full-year 2026 and full-year 2027.
  • Net cash provided by operations was $19.7 million in Q3 2026 versus $22.6 million a year earlier; cash and marketable investment securities totaled $277.7 million as of Sep. 30, 2026.

The filing

CompanyCASTLE BIOSCIENCES INC (CSTL)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001628280-26-071030

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.